TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06539403

Intervention type: BEHAVIORAL
Intervention: Memory tasks
Description: Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall.

Intervention type: BEHAVIORAL
Intervention: Memory tasks
Description: Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall.
Study: NCT05795595

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX131
Description: CTX131 (CD70-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components)
Study: NCT06539403

Intervention type: BEHAVIORAL
Intervention: Memory tasks
Description: Naturalistic Episodic Memory encoding: Participants will play short sessions of 3 board games with the researcher. The board games include Ludo, Snakes \& Ladders and Solitaire. Participants will play each boardgame for around 5 min. They will wear a head camera while playing the games.~Later participants will be tested on their memory of the naturalistic episodic memory task, a semantic memory task (memory of facts) and a perceptual task. Each task will consist of 2-3 sub-tasks of around 30 trials. These tasks will all take place on the computer and will take 30-40 minutes in total. In each trial participants will choose between two options. For example: Which of these two images is taken from your head camera? What colour piece did you use in 'snakes and ladders'?. After they choose their answer, they will report how confident they are in their choice. At the end of each task, they will be asked to report how well they think they performed on the task overall.
Study: NCT05809037

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcutaneous auricular vagus nerve stimulation
Description: In addition to the conventional rehabilitation program, non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, noninvasive auricular stimulation will be applied, stimulation frequency is 10 Hz, pulse width is 300 µs, and biphasic.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: In addition to the conventional rehabilitation program, sham vagus nerve stimulation (0 mA) will be applied to the participants in the control group. Non-invasive vagus nerve stimulation will be applied to the participants through the left ear with the Vagustim™-Ear tens electrode. As a vagus stimulation protocol, 10 sessions, 30 minutes, and noninvasive auricular stimulation will be applied.
Study: NCT05602363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docirbrutinib
Description: oral tablet, twice daily
Study: NCT04761614

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IVPB

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Given PO
Study: NCT06468462

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WHO-recommended periodic presumptive treatment
Description: 400 mg po cefixime plus 1 gram azithromycin po under direct observation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline post-exposure prophylaxis
Description: 200 mg po doxycycline within 24-72 hours after condomless anal or vaginal sex as frequently as daily
Study: NCT05899673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection
Description: Fazirsiran will be injected subcutaneously.
Study: NCT06509737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face to face group
Description: With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase by providing Life with Food Allergy Training based on the Health Promotion Model with face-to-face training in parents of children diagnosed with food allergy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social mediagroup
Description: With this research, it is expected that parents' knowledge levels, symptom management levels for food allergies, and treatment knowledge levels will increase in parents of children diagnosed with food allergy by providing Life with Food Allergy Education based on the Health Promotion Model through social media.
Study: NCT05990712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3
Description: Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trehalose
Description: Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trehalose
Description: Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zocular Eyelid System Treatment
Description: A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zocular Eyelid System Treatment
Description: A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blephadex cleansing eyelid wipes
Description: Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blephadex cleansing eyelid wipes
Description: Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.
Study: NCT05721014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OsteoStrong
Description: This training method is an isometric high-impact loading in four different training machines (Spectrum) and balance training on a vibration plate. The four machines are chest press, leg press, pull-down and deadlift. The participants press and/or pull isometrically for around 10-15 seconds 1-3 times on every machine.~The training session takes around 20 minutes and is performed individually by the participants with the help of a training instructor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Individually Adapted and Combined Physical Training
Description: This training method is based on the current recommendations on physical activity for people with osteoporosis.~The training is divided into two training sessions:~Circuit training with ten stations with different exercises for the whole body (strength, balance, endurance, weight-bearing). The participants spend 40 seconds on each station. This is repeated during 40 minutes. The training session starts with a joint warm-up and ends with a cool-down.~Strength training with machines for the whole body with the intensity of up to 70-80 % of one repetition max (1RM). The training session starts with a joint warm-up and and a voluntary individual cool-down.~The training session takes around 60 minutes and is performed in a group with the help of a training instructor. The participants also have the option to do a home based exercise programme that they could do in a few cases when they were unable to attend the physical group training.
Study: NCT06580574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1 antibody monotherapy, up to 24 weeks
Description: non-specific, according to Drug Instructions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1/PDL1 antibody monotherapy, up to 24 weeks
Description: non-specific, according to Drug Instructions

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks
Description: Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intensive immunotherapy plus anti-VEGF treatment, up to 24 weeks
Description: Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery will be recommended per local treatment standards.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery will be recommended per local treatment standards.
Study: NCT05010148

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: Intravenous lidocaine will be given at 1.33mg/kg/hr (adjusted body weight) for 48 hours following major spinal surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D5 water given at an equivalent ml/hr as intravenous lidocaine (treatment arm) for 48 hours following major spinal surgery
Study: NCT06647095

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-Limonene Gelcaps
Description: Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-Limonene Gelcaps
Description: Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-Limonene Gelcaps
Description: Capsules containing d-Limonene will be optionally given during the breath test to all participants of all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fish Oil Concentrate, 1000 Mg Oral Capsule
Description: Capsules containing fish oil will be optionally given during the breath test to all participants of all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fish Oil Concentrate, 1000 Mg Oral Capsule
Description: Capsules containing fish oil will be optionally given during the breath test to all participants of all groups

Intervention type: DIETARY_SUPPLEMENT
Intervention: Fish Oil Concentrate, 1000 Mg Oral Capsule
Description: Capsules containing fish oil will be optionally given during the breath test to all participants of all groups
Study: NCT06305754

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sacituzumab tirumotecan
Description: 4 mg/kg via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m\^2 via IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 5 mg/mL\*min via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Receptor Antagonist
Description: Administered as rescue medication per approved product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H2 Receptor Antagonist
Description: Administered as rescue medication per approved product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen (or equivalent)
Description: Administered as rescue medication per approved product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone (or equivalent)
Description: Administered as rescue medication per approved product label

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Mouthwash (dexamethasone or equivalent)
Description: Administered as rescue medication per approved product label
Study: NCT05643846

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB procedure after cesarean section
Description: Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QLB procedure after cesarean section
Description: Bupivacaine local anesthetic drug used for QLB procedure after Cesarean section. Intervention of two different concentration of Bupivacaine, 0.125% or 0.25%, at a dose of 0.2 ml/kg.
Study: NCT06399419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CBM588 Capsules
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04813822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Nitrate 2% + Domiphen Bromide Low Dose
Description: Dosage 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miconazole Nitrate 2% + Domiphen Bromide High Dose
Description: Dosage 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Miconazole Nitrate 2%
Description: Active Comparator
Study: NCT06528262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enavogliflozin
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients hospitalized at Severance Hospital for atrial fibrillation catheter ablation, or those who had the procedure within the last three months, will be randomly assigned to receive either 0.3 mg of enavogliflozin once daily or a placebo for 360±30 days
Study: NCT05009628

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: automated oxygenation with a sitting patient position in the ICU
Description: Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated oxygenation with the patient lying down in the ICU
Description: Oxygenation will be done with the Free O2 device via oxygen goggles or a face mask and with an O2 prescription to obtain a SpO2\> 94%. The patient's position in the ICU will be a recumbent position with the head elevated to a maximum of 10

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygenation is controlled with the patient in a sitting position in the ICU.
Description: ICU. Oxygenation will be done via the same interface in manual mode where the post-interventional monitoring room nurse modifies the flow to maintain oxygen saturation above 94%. The patient's position in the ICU will be a sitting position with the chest raised at an angle greater than 45°.
Study: NCT06144814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid vaginal gel
Description: . Group II received 5 mg of vaginal hyaluronic acid every day for 14 days, then 2 days a week for the next 2 weeks. Hyaluronic acid gel for vaginal use was supplied by ORTHOGEN®. The treatment period lasted 1 month in both groups.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogen vaginal use form
Description: Group I received 25 µg vaginal estrodiol (Vagifem®). 1 tablet a day for two weeks, then 2 times a week for the next 2 weeks.
Study: NCT06386575

Intervention type: OTHER
Group type: OTHER
Intervention: control group; Patients who received physiological saline
Description: All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the control group will be given 40 milliliters of physiological saline during the suprainguinal fascia iliaca block.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: suprainguinal fascia block; Patients receiving local anesthetic
Description: All patients will be given 1 gram of paracetamol intravenously + 20 milligrams of tenoxicam + 8 milligrams of decort intravenously. Paracetamol 3x1 gram + tenoxicam 2x20 milligrams will continue to be administered. Patients in the sfıb group will be given 40 milliliters of 0.25 % bupivacaine during the suprainguinal fascia iliaca block.
Study: NCT04818047

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VID-KIDS Intervention Program
Description: Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Videofeedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol.
Study: NCT06192693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsulized fecal microbiota transfer containing the healthy feces + stool dilution solution
Description: 1 FMT=30 capsulized FMT given during 2 days in several intakes per day (3 intakes per day).~FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capsulized placebo transfer containing dilution solution
Description: 1 Placebo of FMT=30 capsulized given during 2 days in several intakes per day (3 intakes per day).~Placebo of FMT will be performed at baseline after randomization. Further treatment(s) will be given again at 6 and 12 weeks if we do not observe a change of Hba1c of at least -0.15% in patients who have Hba1c at inclusion \<7%; of at least -0.4% in patients who have Hba1c at inclusion ≤8% and of at least -0.7% in patients who have Hba1c at inclusion \>8%.
Study: NCT05711017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashibaidu granule
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the Huashibaidu group will receive Huashibaidu granule two times a day for five consecutive days (day 1\~5).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects diagnosed as community-acquired pneumonia in children at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment day, day 0). The subject assigned to the placebo group will receive placebo two times a day for five consecutive days (day 1\~5).
Study: NCT04542109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: READyR A
Description: Two active sessions to conduct an individually-tailored dementia-related needs assessment, incorporating the participant's care values and objective data from remote in-home monitoring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: READyR B
Description: Active comparator. Two sessions to deliver general information about dementia-related care needs.